Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hyman Scott

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
Vaccine|June 29, 2023
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trialsChristine B Turley, LaKesha Tables, Trevon Fuller, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
The Lancet. HIV|May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trialSharana Mahomed, Carmen A Paez, Yunda Huang, et al.
The New England Journal of Medicine|August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
The Lancet. HIV|November 12, 2023
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialRaphael J Landovitz, Brett S Hanscom, Meredith E Clement, et al.
Vaccine|June 29, 2023
Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trialsChristine B Turley, LaKesha Tables, Trevon Fuller, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
The Lancet. HIV|May 11, 2026
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, VRC07-523LS, and PGT121.414.LS infused intravenously or subcutaneously (HVTN 140/HPTN 101 part B): a phase 1, randomised trialSharana Mahomed, Carmen A Paez, Yunda Huang, et al.
The New England Journal of Medicine|August 11, 2021
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenRaphael J Landovitz, Deborah Donnell, Meredith E Clement, et al.
Pageof 5